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patients. In the remaining 92, pre-ASCT PET was positive in 44
and negative in 48. Median follow-up was 8.7 months (range 1-25)
for the entire group and 11.8 months (range 2-25) for surviving
patients. Median remission duration for all patients was 7.1 months
(range 1-25). Patients with a positive and negative pre-ASCT PET
had an estimated 1 year OS of 61% and 77%, respectively (P 
.08). Estimated 1 year EFS was 34% and 66% in patients with
positive and negative pre-ASCT PET, respectively (P  .007). For
the 50 DLBCL patients, median follow up was 6.5 months (range
1-25) for the entire group and 10.3 months (range 2-25) for
survivors. Median EFS for the entire group 6.5 months (range
1-24). Pre-ASCT PET was obtained in 47 patients; 21 (44.6%)
were positive, 26 (55.3%) were negative. 1 year OS was 52% for
patients with a positive pre-ASCT PET and 68% for patients with
a negative pre-ASCT PET (P  .06). 1 year EFS was 40% and
52% for patients with a positive and negative pre-ASCT PET,
respectively (P  .11). Conclusion: Although a negative pre-
ASCT PET in NHL patients does predict a signiﬁcantly better
EFS and a trend toward improved OS, a substantial number of
patients with a positive PET pre-ASCT can achieve a good out-
come and do not require more aggressive therapy. In DLBCL
patients in particular, positive pre-ASCT PET did not predict a
signiﬁcantly worse OS and EFS (Table 1).
Table 1. Overall and Event Free Survival Based on Pre-ASCT
PET Results
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1-y Overall
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Free
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Entire group
(n  100)
49 61 77 .08 34 66 .007
BLBCL
(n  50)
45 52 68 .06 40 52 .11
DLBCL diffuse large B-cell lymphoma.
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We carried out HLA-matched URD peripheral blood stem cell
(PBSC) transplantation in 24 pts with poor-risk multiple myeloma
after nonmyeloablative conditioning with ﬂudarabine (90 mg/m2)
and 2 Gy total body irradiation. Postgrafting immunosuppression
consisted of cyclosporine and mycophenolate mofetil. The median
age of the 19 men and 5 women was 53 (range, 23-66) years.
Conventional metaphase cytogenetics obtained in 14 pts showed
13 in 6 pts and complex abnormalities in 9 pts. Stage III disease
was present in 83% and 17% had stage II disease. The median time
from diagnosis to URD HCT was 25 (range, 8-130) months, and
96% were beyond 1st complete remission (CR) or had never
achieved CR1, despite multiple lines of chemotherapy (median 4.5,
range 2-10). At study entry, 17 pts (71%) had chemotherapy-
refractory disease and 14 pts (58%) had failed prior autologous
HCT. Thirteen pts had planned autologous-URD tandem HCT,
while 11 proceeded directly to URD HCT, with the treatment
plan based on availability of autologous PBSC. The median fol-
low-up was 2.5 years after allografting. One pt experienced non-
fatal graft rejection. The incidences of acute grades II, III and
chronic graft-versus-host disease were 54%, 13% and 75%, respec-
tively. Non-relapse mortality was 22% at 2.5 years. CRs were
observed in 11 pts (46%) and partial remissions (PR) in 3 (13%).
Best disease responses were seen in pts given tandem autologous-
URD HCT with CR in 8 pts and PR in 2 pts (77% CR PR rate).
The estimated overall survival (OS) at 2.5 years for all 24 pts was
65% and progression-free survival (PFS) 41%. Pts receiving tan-
dem autologous-URD HCT had superior OS and PFS, 76% and
63%, compared to pts proceeding directly to URD HCT, 52% and
14%, respectively (PFS P value  .03). Risk factors for worse OS
included pts with signiﬁcant medical comorbidities (P  .03),
chemotherapy-refractory disease prior to HCT (P  .03), and pts
who had failed autologous HCT (P  .07). Pts who failed prior
autologous HCT had 48% OS and 30% PFS at 2.5 years. For pts
with poor-risk, relapsed or refractory multiple myeloma, cytore-
ductive autologous HCT followed with nonmyeloablative condi-
tioning and URD HCT is very promising treatment with low
non-relapse mortality, high complete remission rates and pro-
longed PFS. The results also suggest that URD HCT may provide
improved graft-versus-myeloma effect compared with HLA-
matched sibling HCT without an increase in the risk of non-
relapse mortality.
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Thirty-six patients with chronic B-lymphoproliferative disorders
underwent reduced-intensity allogeneic stem cell transplantation
from 1999 to 2004. Diagnoses included relapsed or refractory
follicular lymphoma (FL) (n  17), mantle cell lymphoma (MCL)
(n  9), small lymphocytic lymphoma (SLL) (n  2), and chronic
lymphocytic leukaemia (CLL) (n  8). The median age at trans-
plant was 51 yrs (range, 30-66 years), time from diagnosis to
transplant was 6 years (range, 0.7 to 9.5 years), and number of prior
treatment regimens was 3 (range, 2 to 6). At the time of transplant
28% of patients were in CR, 36% were in PR, and 36% were
chemorefractory. Thirty-ﬁve patients received peripheral blood
stem cells from an HLA-identical sibling, and one from another
HLA-identical relative. Median number of CD34 stem cells in-
fused was 5.0 106 per kg (range, 0.9-18.9). Conditioning therapy
consisted of ﬂudarabine (125-150 mg/m2) and either cyclophosph-
amide (60-120 mg/kg) (n  27) or melphalan (120-140 mg/m2)
(n  9). Prophylaxis of graft versus host disease (GVHD) included
cyclosporin (CsA) and methotrexate (n  22), CsA and mycophe-
nolate mofetil (n  12), or CsA alone (n  2). Median time to
achievement of an absolute neutrophil count of 	 0.5  109/L and
a platelet count of	 20 109/L was 14 days (range, 8-22 days) and
14 days (range, 8-30 days), respectively. One patient with CLL
failed to engraft despite two donor lymphocyte infusions. Seven
patients died of causes not related to relapse including severe acute
GVHD (n  3), infection, either alone (n  1) or in association
with chronic GVHD (n  2), and intra-abdominal bleeding (n 
1). Treatment-related mortality was 8% at day 100, and 17% at
both one and two years. The cumulative incidence of grades II-IV
acute GVHD was 69% (95% CI, 54-85%). Among evaluable
patients, limited chronic GVHD was seen in 25% and extensive
chronic GVHD in 56%. Of the 33 patients assessable for response,
88% achieved a CR and 9% a PR while one patient had stable
disease. No patients have relapsed or had progressive disease. The
Kaplan-Meier estimate of the proportion of patients alive, and
without disease progression, at a median follow-up of 37 months
(range, 9-69 months) is 83% (95% CI, 76-89%). We conﬁrm that
reduced-intensity allogeneic transplantation in chronic B-lympho-
proliferative disorders can result in high and durable complete
response rates with limited toxicity but with a signiﬁcant incidence
of both acute and chronic GVHD.
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